Vanguard Intl Hi Div Yld Idx ETF
GlaxoSmithKline Is Global Leader in Consumer Healthcare Business
In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 2.0 billion pounds from the sale of its consumer healthcare products, which is year-over-year (or YoY) growth of 5% on a reported basis and 2% on a constant exchange rate (or CER).
Nucala May Be a Game-Changing Product in Respiratory Segment
On December 12, 2017, the FDA expanded Nucala’s label and approved the therapy for patients suffering from eosinophilic granulomatosis with polyangiitis (or EGPA).
Will ZBH Beat Wall Street Earnings Estimates in 4Q17?
Zimmer Biomet Holdings (ZBH) accounts for ~0.17% of the total holdings of the Vanguard International High Dividend Yield ETF (VYMI). Zimmer Biomet Holdings plans to announce its 4Q17 and fiscal 2017 earnings results on January 30.
How AstraZeneca’s CVMD Products Performed in 3Q17
The CVMD segment reported revenues of $1.8 billion during 3Q17, a 4% decline in operating revenues driven by lower sales of Bydureon, Crestor, Onglyza, and Seloken.
AstraZeneca’s Brilinta and Farxiga Posted High Growth in 3Q17
Brilinta generated 9M17 revenues of ~$175.0 million from emerging markets, which reflected 29.0% YoY growth.
How Novartis’s Tasigna Is Looking Now
In 3Q17, Novartis’s (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).
Investor Updates on Novartis’s Immunology and Dermatology Portfolio
In 1H17, Novartis’s (NVS) Neoral/Sandimmune reported revenues of around $238 million, which reflected an ~8% decline on a year-over-year (or YoY) basis.
Host Hotels & Resorts’ Dividend Yield over the Years
Revenue and earnings Host Hotels & Resorts (HST), a hotel REIT, is involved in the possession and operation of US hotel properties. The company’s revenue was almost flat in 2015 and 2016, driven by rooms and food and beverages. Its operating costs and expenses rose 1%–2% in 2015 and 2016., while its interest expenses fell 32% […]
Performance of AstraZeneca’s Respiratory Segment in 2Q17
Pulmicort, a drug for the prevention of asthma attacks, reported revenues of $226 million during 2Q17, a 3% decline at constant exchange rates compared to 2Q16.